Fritz L. LaPorte CPA serves as Independent Director of the Company. Mr. LaPorte is a Partner at Dovere Advisory Group, LLC, which he co-founded in October 2014 to guide early stage operating growth companies primarily in the medical device and healthcare sectors, in creating and sustaining value while reducing risk in the process. Mr. LaPorte co-founded MAKO Surgical Corp., an orthopedic surgical robotic company, in November 2004 and served as its Senior Vice President, Chief Financial Officer and Treasurer to December 2013, which was acquired by Stryker Corporation (formerly NASDAQ:MAKO). Mr. LaPorte subsequently served as Vice President and Chief Financial Officer of Stryker Corporation – Stryker Mako Business Unit from December 2013 to June 2014 to assist in the integration of MAKO Surgical Corp. into Stryker Corporation. Since January 2018, he also serves on the board of directors and finance committee of Holy Cross Hospital in Fort Lauderdale, Florida and, since January 2020, serves as the vice chair of the board of directors, chair of the governance committee and member of the executive committee. Mr. LaPorte holds a Bachelors of Business Administration in Accounting from Florida Atlantic
As the Independent Director of Venus Concept, the total compensation of Fritz LaPorte at Venus Concept is 100,400$. There are 7 executives at Venus Concept getting paid more, with Domenic Serafino having the highest compensation of 763,479$.
Fritz LaPorte is 50, he's been the Independent Director of Venus Concept since 2019. There are 12 older and 10 younger executives at Venus Concept. The oldest executive at Venus Concept Inc. is Kenji Shimizu, 68, who is the Interim Chief Innovation Officer.
Fritz's mailing address filed with the SEC is C/O MAKO SURGICAL CORP., 2555 DAVIE ROAD, FORT LAUDERDALE, FL, 33317.
Over the last 5 years, insiders at Venus Concept have traded over 1,569,538$ worth of Venus Concept stock and bought 13,477,963 units worth 14,979,486$ . The most active insiders traders include Healthcare Partners, L.P.Ew...、Gilbert H Kliman、Richard Scott Barry. On average, Venus Concept executives and independent directors trade stock every 46 days with the average trade being worth of 222,494$. The most recent stock trade was executed by Michael Willingham Masters ... on 7 June 2024, trading 489,948 units of VERO stock currently worth 587,938$.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes aesthetic device platforms, including Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; and Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss, a device for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; and ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Venus Concept executives and other stock owners filed with the SEC include: